SIRT1 and HSP90α feed-forward circuit safeguards chromosome segregation integrity in diffuse large B cell lymphomas.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
11 10 2023
11 10 2023
Historique:
received:
20
01
2023
accepted:
28
09
2023
revised:
18
09
2023
medline:
12
10
2023
pubmed:
11
10
2023
entrez:
10
10
2023
Statut:
epublish
Résumé
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma in adults, exhibiting highly heterogenous clinical behavior and complex molecular background. In addition to the genetic complexity, different DLBCL subsets exhibit phenotypic features independent of the genetic background. For example, a subset of DLBCLs is distinguished by increased oxidative phosphorylation and unique transcriptional features, including overexpression of certain mitochondrial genes and a molecular chaperone, heat shock protein HSP90α (termed "OxPhos" DLBCLs). In this study, we identified a feed-forward pathogenetic circuit linking HSP90α and SIRT1 in OxPhos DLBCLs. The expression of the inducible HSP90α isoform remains under SIRT1-mediated regulation. SIRT1 knockdown or chemical inhibition reduced HSP90α expression in a mechanism involving HSF1 transcription factor, whereas HSP90 inhibition reduced SIRT1 protein stability, indicating that HSP90 chaperones SIRT1. SIRT1-HSP90α interaction in DLBCL cells was confirmed by co-immunoprecipitation and proximity ligation assay (PLA). The number of SIRT1-HSP90α complexes in PLA was significantly higher in OxPhos- dependent than -independent cells. Importantly, SIRT1-HSP90α interactions in OxPhos DLBCLs markedly increased in mitosis, suggesting a specific role of the complex during this cell cycle phase. RNAi-mediated and chemical inhibition of SIRT1 and/or HSP90 significantly increased the number of cells with chromosome segregation errors (multipolar spindle formation, anaphase bridges and lagging chromosomes). Finally, chemical SIRT1 inhibitors induced dose-dependent cytotoxicity in OxPhos-dependent DLBCL cell lines and synergized with the HSP90 inhibitor. Taken together, our findings define a new OxPhos-DLBCL-specific pathogenetic loop involving SIRT1 and HSP90α that regulates chromosome dynamics during mitosis and may be exploited therapeutically.
Identifiants
pubmed: 37816710
doi: 10.1038/s41419-023-06186-0
pii: 10.1038/s41419-023-06186-0
pmc: PMC10564908
doi:
Substances chimiques
HSP90 Heat-Shock Proteins
0
Molecular Chaperones
0
SIRT1 protein, human
EC 3.5.1.-
Sirtuin 1
EC 3.5.1.-
HSP90AA1 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
667Informations de copyright
© 2023. The Author(s).
Références
Science. 2004 Mar 26;303(5666):2011-5
pubmed: 14976264
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13134-9
pubmed: 17670934
Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):E187-96
pubmed: 22190494
Nature. 2016 Oct 20;538(7625):397-401
pubmed: 27706135
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):E4134-41
pubmed: 24133140
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Blood. 2017 Sep 21;130(12):1418-1429
pubmed: 28698206
Br J Haematol. 2009 Feb;144(3):358-66
pubmed: 19036086
Cancer Lett. 2017 Dec 28;411:19-26
pubmed: 28987383
Nat Med. 2009 Dec;15(12):1369-76
pubmed: 19966776
Nat Genet. 2002 Dec;32(4):606-13
pubmed: 12402037
Nat Rev Clin Oncol. 2014 Jan;11(1):12-23
pubmed: 24217204
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
Pharmacol Ther. 2018 Aug;188:140-154
pubmed: 29577959
Cells. 2022 Sep 06;11(18):
pubmed: 36139353
Oncogene. 2004 Apr 12;23(16):2825-37
pubmed: 15077146
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12
pubmed: 17360630
Cancer Res. 2021 Oct 15;81(20):5202-5216
pubmed: 34479963
Science. 2009 Feb 20;323(5917):1063-6
pubmed: 19229036
Cancers (Basel). 2020 Mar 03;12(3):
pubmed: 32138178
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
Ageing Res Rev. 2018 May;43:64-80
pubmed: 29476819
Blood. 2005 Mar 1;105(5):1851-61
pubmed: 15550490
Cell. 2001 Oct 19;107(2):149-59
pubmed: 11672523
Cancer Res. 2021 Dec 1;81(23):6029-6043
pubmed: 34625423
Front Mol Neurosci. 2018 Jan 09;10:443
pubmed: 29375306
Cell Death Differ. 2017 Feb;24(2):251-262
pubmed: 27768122
J Cell Biochem. 2015 Sep;116(9):1888-97
pubmed: 25737075
Blood. 2009 Apr 2;113(14):3276-86
pubmed: 19196867
Cell. 2001 Oct 19;107(2):137-48
pubmed: 11672522
Antioxid Redox Signal. 2018 Mar 10;28(8):643-661
pubmed: 28891317
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
Biochem J. 2016 Aug 15;473(16):2439-52
pubmed: 27515256
Nat Med. 2015 Aug;21(8):922-6
pubmed: 26193343
Breast Cancer Res. 2019 May 17;21(1):64
pubmed: 31101119
Leukemia. 2020 Aug;34(8):2184-2197
pubmed: 32060403
Nat Rev Cancer. 2018 Sep;18(9):562-575
pubmed: 29795326
Blood. 2019 Jan 3;133(1):70-80
pubmed: 30322870
Am J Surg Pathol. 2008 Oct;32(10):1523-31
pubmed: 18724249
Nucleic Acids Res. 2017 Jul 27;45(13):7807-7824
pubmed: 28549174
Leuk Lymphoma. 2022 Jan;63(1):54-63
pubmed: 34510995
Genes Cancer. 2013 Mar;4(3-4):82-90
pubmed: 24019998
Cancer Cell. 2008 May;13(5):454-63
pubmed: 18455128
J Drug Target. 2019 Dec;27(10):1046-1052
pubmed: 31056963
Blood. 2014 Jul 3;124(1):121-33
pubmed: 24855208
J Clin Invest. 2015 Nov 03;125(12):4559-71
pubmed: 26529251
Blood Adv. 2018 Aug 28;2(16):2039-2051
pubmed: 30115641
Int J Mol Sci. 2018 Aug 29;19(9):
pubmed: 30158430
Oncogene. 2016 Nov 17;35(46):5989-6000
pubmed: 27132507
Cell Death Dis. 2013 Apr 18;4:e603
pubmed: 23598415
Leukemia. 2020 Jul;34(7):1828-1839
pubmed: 31896781
J Mol Biol. 2015 Apr 10;427(7):1644-54
pubmed: 25688804
Mol Cell Proteomics. 2012 Oct;11(10):1048-62
pubmed: 22826441
Mol Cell Oncol. 2020 Jan 16;7(2):1709390
pubmed: 32158924
Nature. 2005 Mar 3;434(7029):113-8
pubmed: 15744310
J Biol Chem. 2003 Dec 26;278(52):52572-7
pubmed: 14570880
Cell Rep. 2018 Dec 4;25(10):2851-2865.e3
pubmed: 30517871
J Cell Mol Med. 2018 Jul;22(7):3548-3559
pubmed: 29665227
Cell Death Dis. 2019 May 1;10(5):363
pubmed: 31043584
Cancer Cell. 2012 Oct 16;22(4):547-60
pubmed: 23079663
Nat Rev Mol Cell Biol. 2011 Jun;12(6):385-92
pubmed: 21527953
Curr Cancer Drug Targets. 2016;16(4):305-22
pubmed: 26517536
Lancet Oncol. 2013 Aug;14(9):e358-69
pubmed: 23896275
Mol Cancer Ther. 2017 Sep;16(9):1779-1790
pubmed: 28619753